Skip to main content

DUBLIN–(BUSINESS WIRE)–The “Monoclonal Antibody Market Size, Share and Trend Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In Vivo, In Vitro), By Application, By End Use, By Region, and Segment Forecasts, 2022-2030” report has been added to from offer.

The global monoclonal antibody market is expected to reach USD 494.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.30%

Rising research and development activities aimed at developing novel therapeutic monoclonal antibodies (mAbs) and government initiatives supporting the production of biologics are expected to drive the market growth during the forecast period.

The growing demand for personalized medicine is likely to positively affect the development of therapeutic mAb-targeted therapies tailored to individual needs. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment and large-scale production capabilities, compared to conventional treatment options, and can significantly stimulate the growth of the market.

Additionally, several government entities are fueling clinical research activities and expanding the scope of mAb therapies. For example, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for reducing asthma attacks and improving lung functionality in children.

Similarly, in March 2021, the US Department of Health and Human Services invested $150 million to increase patient access to therapeutic monoclonal antibodies against COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen growth prospects.

Additionally, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. The demand for such recombinant antibodies is driven by growing commercial prospects and quality requirements that may not be met by hybridoma technologies. Hence, with the growing commercial viability of recombinant technologies, the market is expected to witness significant growth.

The COVID-19 pandemic has created several opportunities for market expansion by fueling the development of several mAbs directed against the SARS-CoV-2 virus.

As mAbs represent a promising alternative for disease mitigation due to their safety and efficacy, several mAbs such as Eli Lilly’s bebtelovimab and GlaxoSmithKline & Vir Biotechnology’s sotrovimab have obtained emergency use authorizations from from the US FDA. Such permissions are likely to broaden the growth horizons of mAbs applications and propel the growth of the market.

Monoclonal Antibodies Market Report Highlights

  • By source type, human mAb segment held the largest share of 54.07% in 2021 due to low immunogenicity offered and increasing cancer treatment applications of these antibodies

  • The in vitro production type held a dominant share of 78.45% in 2021 due to the low levels of contamination offered by the technique and the availability of advanced biomanufacturing capabilities

  • Oncology segment led the market in 2021 owing to increasing number of approvals for mAb cancer therapies and increasing awareness among scientists and patients about these therapies

  • Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and rising healthcare expenditures driving the adoption of these therapeutics

  • North America accounted for 46.2% of the market value in 2021 due to availability of advanced healthcare infrastructure, strong growth in cancer incidence and local presence of key players such as Pfizer Inc., Amgen, Inc. and Merck & Co., among others

  • Asia-Pacific is expected to witness the highest growth rate during the forecast period owing to the availability of a large number of patients for cancer treatment and the widening scope of research prospects clinic for mAbs.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

2.1 Market Outlook

2.2 Market Summary

Chapter 3 Monoclonal Antibody Market Variables, Trends and Scope

3.1 Market Trends and Outlook

3.2 Market Segmentation and Scope

3.3 Market Driver Analysis

3.3.1 Increase in the incidence of chronic diseases

3.3.2 Technological advances

3.3.3 Increasing levels of awareness

3.4 Market Restraint Analysis

3.4.1 High cost of therapeutic Mabs

3.5 SWOT Analysis, by Factor (Political & Legal, Economic & Technological)

3.6 Porter’s Five Forces Analysis

3.7 COVID-19 Impact Analysis

3.8 Mapping penetration and growth prospects

Chapter 4 Monoclonal Antibodies Market- Segment Analysis, by Source Type, 2018-2030 (USD Billion)

4.1 Monoclonal Antibodies Market: Source Type Movement Analysis

4.2 Murine

4.2.1 Murine Market Estimates and Forecasts, 2018- 2030 (USD Billion)

4.3 Chimera

4.4 Humanized

4.5 Human

Chapter 5 Monoclonal Antibodies Market- Segment Analysis, by Production Type, 2018-2030 (USD Billion)

5.1 Monoclonal Antibodies Market: Production Type Movement Analysis

5.2 In Vivo

5.2.1 In Vivo Market Estimates and Forecast, 2018- 2030 (USD Billion)

5.3 In Vitro

Chapter 6 Monoclonal Antibodies Market- Segment Analysis, by Application, 2018-2030 (USD Billion)

6.1 Monoclonal Antibodies Market: Application Movement Analysis

6.2 Oncology

6.2.1 Oncology Market Estimates and Forecasts, 2018- 2030 (USD Billion)

6.3 Autoimmune diseases

6.4 Infectious Diseases

6.5 Neurological diseases

Chapter 7 Monoclonal Antibodies Market- Segment Analysis, by end-use, 2018-2030 (USD Billion)

7.1 Monoclonal Antibodies Market: End-Use Movement Analysis

7.2 Hospitals

7.2.1 Hospitals Market Estimates and Forecasts, 2018-2030 (USD Billion)

7.3 Specialized centers

Chapter 8 Monoclonal Antibodies Market- Segment Analysis, by Region, 2018-2030 (USD Billion)

8.1 Monoclonal Antibodies Market: Regional Movement Analysis

Chapter 9 Competitive Analysis

  • Abbott Laboratories

  • Amgen Inc.

  • Astrazeneca plc

  • Bayer AG

  • Biogene Inc.

  • Bristol Myers Squibb

  • Daiichi Sankyo Company, Limited

  • Eli Lilly and company

  • F. Hoffman-La Roche Ltd.

  • GlaxoSmithKline plc

  • Johnson & Johnson Services, Inc.

  • Merck & Co. Inc.

  • Merck Kgaa

  • Novartis AG

  • Novo Nordisk A/S

  • Pfizer Inc.

  • Sanofi SA

  • ThermoFisher Scientific, Inc.

  • Viatris inc.

For more information about this report visit